40 results
424B5
SLNO
Soleno Therapeutics Inc
29 Sep 23
Prospectus supplement for primary offering
4:51pm
develop;
injury to our reputation and significant negative media attention;
withdrawal of patients from clinical studies or cancellation of studies … to, successfully commercialize our product candidates.
S-29
If we use hazardous materials in a manner that causes injury, we could be liable
424B5
SLNO
Soleno Therapeutics Inc
27 Sep 23
Prospectus supplement for primary offering
5:26pm
that we may develop;
injury to our reputation and significant negative media attention;
withdrawal of patients from clinical studies or cancellation … in our efforts to, successfully commercialize our product candidates.
S-29
If we use hazardous materials in a manner that causes injury, we could
424B5
l9df2d n0izccrx8amnc
30 Mar 22
Prospectus supplement for primary offering
5:21pm
424B5
z17af
28 Mar 22
Prospectus supplement for primary offering
4:53pm
8-K
EX-10.1
a8bqbr
30 Dec 21
Entry into a Material Definitive Agreement
4:37pm
424B5
6z3cg0ye7sywat95lt8
25 Jun 20
Prospectus supplement for primary offering
4:01pm
424B5
ymbzmi9d0w dozr191
23 Jun 20
Prospectus supplement for primary offering
4:06pm
424B5
rs0s09bo9l2map vvm
25 Oct 19
Prospectus supplement for primary offering
12:00am
424B5
yuihu
22 Oct 19
Prospectus supplement for primary offering
4:24pm
424B3
aeccyfxxi9q cqc428t
12 Apr 19
Prospectus supplement
4:41pm